Charles Schwab Investment Management Inc. Buys 51,810 Shares of Progyny, Inc. $PGNY

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Progyny, Inc. by 8.1% during Q1, now holding approximately 0.80% of shares valued at $15.4 million.
• Progyny reported earnings of $0.19 EPS, missing estimates, while revenue for the quarter was $332.87 million, surpassing expectations.
• Wall Street analysts have a consensus "Moderate Buy" rating for Progyny, with an average target price of $25.10 per share.

Charles Schwab Investment Management Inc. grew its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 8.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 689,443 shares of the company's stock after buying an additional 51,810 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.80% of Progyny worth $15,402,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of PGNY. Natixis purchased a new stake in shares of Progyny during the fourth quarter valued at approximately $69,000. GAMMA Investing LLC grew its stake in Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after purchasing an additional 3,768 shares during the period. State of Wyoming increased its position in shares of Progyny by 98.2% during the 4th quarter. State of Wyoming now owns 12,376 shares of the company's stock valued at $213,000 after purchasing an additional 6,132 shares during the last quarter. Cerity Partners LLC bought a new stake in shares of Progyny during the 4th quarter worth $229,000. Finally, XTX Topco Ltd purchased a new position in shares of Progyny in the 1st quarter worth about $241,000. Hedge funds and other institutional investors own 94.93% of the company's stock.

Insider Activity at Progyny

In other Progyny news, Director Kevin K. Gordon sold 2,500 shares of the firm's stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the transaction, the director directly owned 12,501 shares of the company's stock, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Scott sold 2,675 shares of the company's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the transaction, the director directly owned 14,112 shares in the company, valued at approximately $311,451.84. The trade was a 15.93% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 9.40% of the company's stock.

Progyny Stock Down 1.7%

Shares of NASDAQ:PGNY traded down $0.39 during midday trading on Monday, reaching $23.14. 825,635 shares of the company traded hands, compared to its average volume of 1,131,317. The firm's fifty day moving average price is $22.55 and its two-hundred day moving average price is $22.17. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of 42.78, a price-to-earnings-growth ratio of 1.92 and a beta of 1.32. Progyny, Inc. has a 12 month low of $13.39 and a 12 month high of $26.76.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. During the same quarter in the prior year, the company earned $0.17 earnings per share. The company's quarterly revenue was up 9.5% on a year-over-year basis. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts forecast that Progyny, Inc. will post 0.6 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $28.00 price objective (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Canaccord Genuity Group raised their price target on shares of Progyny from $21.00 to $23.00 and gave the stock a "hold" rating in a research note on Wednesday, August 20th. Wall Street Zen raised shares of Progyny from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. Truist Financial increased their price objective on Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a report on Thursday, July 17th. Finally, Leerink Partners raised Progyny from a "market perform" rating to an "outperform" rating and set a $28.00 target price for the company in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.10.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.